TY - JOUR
T1 - The role of stakeholder involvement in the evolving EU HTA process
T2 - Insights generated through the European Access Academy's multi-stakeholder pre-convention questionnaire.
AU - Van Haesendonck, Lauren
AU - Ruof, Jörg
AU - Desmet, Thomas
AU - Van Dyck, Walter
AU - Simoens, Steven
AU - Huys, Isabelle
AU - Giuliani, Rosa
AU - Toumi, Mondher
AU - Dierks, Christian
AU - Dierks, Juliana
AU - Cardone, Antonella
AU - Houÿez, Francois
AU - Pavlovic, Mira
AU - Berntgen, Michael
AU - Mol, Peter G M
AU - Schiel, Anja
AU - Goettsch, Wim
AU - Gianfrate, Fabrizio
AU - Capri, Stefano
AU - Ryan, James
AU - Ducournau, Pierre
AU - Solà-Morales, Oriol
AU - Julian, Elaine
N1 - Publisher Copyright:
© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023/6/4
Y1 - 2023/6/4
N2 - Involvement of all relevant stakeholders will be of utmost importance for the success of the developing EU HTA harmonization process. A multi-step procedure was applied to develop a survey across stakeholders/collaborators within the EU HTA framework to assess their current level of involvement, determine their suggested future role, identify challenges to contribution, and highlight efficient ways to fulfilling their role. The 'key' stakeholder groups identified and covered by this research included: patients', clinicians', regulatory, and Health Technology Developer representatives. The survey was circulated to a wide expert audience including all relevant stakeholder groups in order to determine self-perception by the 'key' stakeholders regarding involvement in the HTA process (self-rating), and in a second, slightly modified version of the questionnaire, to determine the perception of 'key' stakeholder involvement by HTA bodies, payers, and policymakers (external rating). Predefined analyses were conducted on the submitted responses. Fifty-four responses were received (patients 9; clinicians: 8; regulators: 4; HTDs 14; HTA bodies: 7; Payers: 5; policymakers 3; others 4). The mean self-perceived involvement score was consistently lower for each of the 'key' stakeholder groups than the respective external ratings. Based on the qualitative insights generated in the survey, a RACI Chart (Responsible/Accountable/Consulted/Informed) was developed for each of the stakeholder groups to determine their roles and involvement in the current EU HTA process. Our findings suggest extensive effort and a distinct research agenda are required to ensure adequate involvement of the key stakeholder groups in the evolving EU HTA process.
AB - Involvement of all relevant stakeholders will be of utmost importance for the success of the developing EU HTA harmonization process. A multi-step procedure was applied to develop a survey across stakeholders/collaborators within the EU HTA framework to assess their current level of involvement, determine their suggested future role, identify challenges to contribution, and highlight efficient ways to fulfilling their role. The 'key' stakeholder groups identified and covered by this research included: patients', clinicians', regulatory, and Health Technology Developer representatives. The survey was circulated to a wide expert audience including all relevant stakeholder groups in order to determine self-perception by the 'key' stakeholders regarding involvement in the HTA process (self-rating), and in a second, slightly modified version of the questionnaire, to determine the perception of 'key' stakeholder involvement by HTA bodies, payers, and policymakers (external rating). Predefined analyses were conducted on the submitted responses. Fifty-four responses were received (patients 9; clinicians: 8; regulators: 4; HTDs 14; HTA bodies: 7; Payers: 5; policymakers 3; others 4). The mean self-perceived involvement score was consistently lower for each of the 'key' stakeholder groups than the respective external ratings. Based on the qualitative insights generated in the survey, a RACI Chart (Responsible/Accountable/Consulted/Informed) was developed for each of the stakeholder groups to determine their roles and involvement in the current EU HTA process. Our findings suggest extensive effort and a distinct research agenda are required to ensure adequate involvement of the key stakeholder groups in the evolving EU HTA process.
KW - EUHTA
KW - Health policy
KW - Health technology assessment
KW - Stakeholder involvement
UR - https://www.scopus.com/pages/publications/85163012452
U2 - 10.1080/20016689.2023.2217543
DO - 10.1080/20016689.2023.2217543
M3 - Article
C2 - 37284060
SN - 2001-6689
VL - 11
JO - Journal of market access & health policy
JF - Journal of market access & health policy
IS - 1
M1 - 2217543
ER -